Series B Round

NewLimit is an anti-aging startup focused on epigenetic reprogramming, aiming to increase the healthy lifespan of individuals by genetically programming their cells. The company is leveraging cutting-edge biotechnology to develop therapies that could potentially reverse aging at the cellular level. Founded by Coinbase CEO Brian Armstrong and geneticist Blake Richards, NewLimit is at the forefront of the biotech industry, seeking to revolutionize how we approach aging and health. The startup's innovative approach combines advanced genetic engineering techniques with a vision to enhance longevity and overall well-being. The company aims to provide solutions that not only extend lifespan but also improve the quality of life for aging populations. With a strong focus on research and development, NewLimit is positioned to lead the charge in the emerging field of age-reversal therapies.